In both trials, Journavx outperformed a placebo. Unlike Vicodin, which changes the brain’s perception of pain and can lead to addiction, Journavx works only on nerves outside the brain ...
Opioids reduce pain by binding to receptors in the brain that receive nerve signals ... case scenario for this key pipeline program,” biotechnology analyst Brian Abrahams said in a research ...
What do we see in the bustling corridors of Silicon Valley, the research labs of Boston, and the biotech hubs of San ... earlier considered to be “brain-drain”, is now being looked at as ...
National Coordinator, the Nigeria Reduced Emissions from Deforestation and Degradation (REDD ) Programme, Salisu Dahiru, has called on state governments in Nigeria to embrace... The African Union ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers.
Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...
Prolium was set up by RTW in 2024. Last year also saw the New York-based investment fund involved in the launch of obesity biotech Kailera Therapeutics, which RTW said at the time was the fourth ...
But local biotech leaders see signs of change in 2025. Amid tough biotech industry market conditions last year, investors and Big Pharma companies were more likely to make deals with later-stage ...
The Biotech Beach Hotbed includes San Diego, Los Angeles and the surrounding (Torrey Pines, Thousand Oaks) regions of Southern California. SoCal is well-known for its sprawling beaches and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback